Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
OMIM | RCV000023915 | SCV000045206 | pathogenic | Hydatidiform mole, recurrent, 2 | 2013-09-01 | no assertion criteria provided | literature only | |
Prevention |
RCV004758598 | SCV005367159 | pathogenic | KHDC3L-related condition | 2024-05-31 | no assertion criteria provided | clinical testing | The KHDC3L c.322_325delGACT variant is predicted to result in a frameshift and premature protein termination (p.Asp108Ilefs*30). This variant has been reported in the homozygous or compound heterozygous state in individuals with recurrent hydatidiform moles or pregnancy loss (Parry et al. 2011. PubMed ID: 21885028; Reddy et al. 2012. PubMed ID: 23232697; Fatemi et al. 2021. PubMed ID: 33639414). This variant is reported in 0.0065% of alleles in individuals of South Asian descent in gnomAD. Frameshift variants in KHDC3L are expected to be pathogenic. This variant is interpreted as pathogenic. |